Cost Breakthrough: Advanced Melanoma Treatment Subsidized for Australians

The Australian government is set to reduce the cost of advanced melanoma treatment through the Pharmaceutical Benefits Scheme (PBS).

Health Minister Mark Butler announced that Opdualag, a combination of immunotherapies for recurrent or metastatic melanoma, will be subsidized for patients aged over 12.

Approximately 940 patients will benefit from the PBS subsidy, with a significant reduction in treatment costs, making it more accessible for those living with advanced-stage melanoma.

Patients previously faced costs exceeding $315,000, but with the PBS listing, their maximum expense will now be at PBS prices.

This move is expected to positively impact millions of Australians dealing with ongoing health conditions, ensuring they can afford essential treatments without financial strain.

Tamara Dawson, CEO of the Melanoma and Skin Cancer Advocacy Network, welcomed the reimbursement, emphasizing the importance of diverse treatment options.

Professor Georgina Long AO, co-medical director of Melanoma Institute Australia, stressed the necessity of accessible treatments, considering Australia’s high rates of melanoma, the most commonly diagnosed cancer among young Australians.

In 2022 alone, over 17,700 people were estimated to be diagnosed with melanoma, leading to 1281 deaths.